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Abstract
Background: Tristetraprolin (TTP) is a key mediator of processes such as inflammation resolution, the inhibition of
autoimmunity and in cancer. It carries out this role by the binding and degradation of mRNA transcripts, thereby
decreasing their half-life. Transcripts modulated by TTP encode proteins such as cytokines, pro-inflammatory agents
and immediate-early response proteins. TTP can also modulate neoplastic phenotypes in many cancers. TTP is
induced and functionally regulated by a spectrum of both pro- and anti-inflammatory cytokines, mitogens and
drugs in a MAPK-dependent manner. So far the contribution of p38 MAPK to the regulation of TTP expression and
function has been best described.
Results: Our results demonstrate the induction of the gene coding TTP (ZFP36) by EGF through the ERK1/2-dependent
pathway and implicates the transcription factor ELK-1 in this process. We show that ELK-1 regulates ZFP36 expression by
two mechanisms: by binding the ZFP36 promoter directly through ETS-binding site (+ 883 to +905 bp) and by inducing
expression of EGR-1, which in turn increases ZFP36 expression through sequences located between -111 and -103 bp.
Conclusions: EGF activates TTP expression via ELK-1 and EGR-1 transcription factors.
Background
Gene ZFP36 encodes for tristetraprolin (TTP, also known
as G0S24, ZFP36, TIS11, and Nup475). The gene product
is the prototype of the tandem CCCH zinc finger protein
family, called TIS11, which includes four structurally and
sequentially related proteins - TTP, BRF-1, BRF-2 and
ZFP36L3 [1]. TIS11 family members feature a conserved
non-typical tandem zinc finger domain that mediates its
interaction with target RNA species [2]. TTP is the most
thoroughly described member of the TIS11 family, and
has been identified as a nucleo-cytoplasmic protein that
specifically binds mRNAs containing Adenine/Uridine-
Rich Elements (AREs) in their 3’-UTRs (3’-untranslated
regions) and directs them to exosome- or P-body-
mediated degradation [3]. Genome-wide experiments
have revealed many potential targets for TTP-mediated
degradation. A more direct approach confirmed that
TTP interacts with transcripts encoding for a number of
cytokines (TNFa, IL-1b, IL-2, IL-6, GM-CSF), pro-
inflammatory factors (iNOS, COX-2), proteins which
have important roles in breast cancer invasion and
metastasis (urokinase, urokinase receptor, metalloprotei-
nase-1, VEGF), immediate-early response proteins like c-
FOS and tristetraprolin itself [4-6].
The activity of TTP is regulated predominantly via its
phosphorylation by MAP kinases (in particular p38 and
ERK1/2), kinases downstream of MAPKs (including
MK2, the p38 substrate or MK3) or AKT in response to
pro-inflammatory cytokines (TNFa, IL-1b, IFNg), LPS
and anti-inflammatory factors (TGFb, dexamethasone).
The TTP protein sequence contains several key serine/
threonine residues, the modification of which was pre-
viously shown to determine the ability of TTP to recruit
the mRNA-degradation machinery, bind transcripts, be
shuttled to P-bodies or stress granules and its nuclear/
cytoplasmic localization and protein stability [7-12].
Less is known about the regulation of TTP expression.
Both mRNA and protein are induced rapidly after stimu-
lation of the cells with pro- and anti-inflammatory factors
(TNFa, LPS, IL-1b, IL-4, TGFb, IFNg, glucocorticoids as
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well as mitogenic factors such as those found in serum,
or phorbol esters) [11,13-18]. The structure of the mur-
ine Zfp36 gene promoter has been characterized, with
the identification of a conserved proximal EGR-1 tran-
scription factor binding site, AP2, SP1, TTP promoter
element 1, STAT6 and SMAD biding sites and a func-
tional GAS element. The first intron has also been shown
to play a key role in mitogen-induced expression of
Zfp36 [18,19].
The ELK-1 transcription factor is a representative
member of ETS protein family characterized by the pre-
sence of the evolutionary conserved ETS domain stabi-
lized by three key tryptophan residues and responsible
for the interaction with DNA [20]. The ELK-1 domain
structure includes an ETS domain (known also as Box A)
at the N-terminus, Box B domain in the middle part of
the sequence and C-terminal transactivation domain
(TAD, Box C). Box B is also found in other members of
TCF (Ternary Complex Factor) subfamily (SAP-1, SAP-
2) and is relevant for the formation of ternary complex
with SRF (Serum Responsive Factor) on SREs (Serum
Response Element) [21]. Box A is a site of recruitment of
the mSIN3A/HDAC1 complex, which confers the repres-
sor function of ELK-1 [22]. HDAC-2 is recruited to ELK-
1 through the repressive R-motif in SUMO-dependent
manner. The phosphorylation of the TAD serine/threo-
nine residues is crucial for switching from repression to
activation of transcription [23]. The phosphorylation is
catalyzed mainly by MAPKs such as ERK1/2 and Ser383
phosphorylation serves as a hallmark of ELK-1 activation.
Only a handful of the genes directly targeted by ELK-1
are known. Among them EGR-1 and FOS seem to have
the most important function in the regulation of the
immediate-early cell response and widen the spectrum of
ELK-1-regulated genes [24,25]. The role of ELK-1 in the
regulation of immunological response has also been
emphasized [26].
Results
EGF regulates tristetraprolin expression in ERK1/2-
dependent manner
Stimulation of the human breast cancer MCF-7 cell line
with EGF resulted in a rapid induction of TTP expres-
sion, the maximal effect being observed 30 minutes after
EGF treatment. The ERK1/2 pathway inhibitor, U0126,
inhibited this process (Figure 1A). In order to confirm
the involvement of EGF in the activation of ERK1/2 in
the MCF-7 cell line we performed western blot analysis
using anti-phospho ERK1/2, anti-phospho p38 and anti-
phospho JNK antibodies. We found that EGF was a spe-
cific activator of ERK1/2 phosphorylation in this system
(Figure 1B). We were unable to detect the phosphoryla-
tion of JNK or p38 after EGF treatment whereas PMA
treatment induced phosphorylation of all tested MAP
kinases (Figure 1B). We concluded that EGF activates
the ERK1/2 pathway in the MCF-7 cell line and that
activation of this pathway resulted in increase of TTP
mRNA.
Figure 1 (A) TTP mRNA expression upon EGF stimulation. Serum-starved MCF-7 cells were stimulated with EGF (20 ng/ml) for indicated
times. The total RNA was extracted and analyzed by Real Time PCR using ZFP36 specific primers. (B) Activation of ERK1/2 pathway upon EGF
stimulation. Serum-starved MCF-7 cells were stimulated with EGF (20 ng/ml) or PMA (100 ng/ml) for indicated times, harvested and subjected
to Western blot analysis (with anti-phospho ERK1/2, anti-ERK1/2, anti-phospho p38, anti-p38, anti-phospho JNK and anti-JNK antibodies)
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Regulation of ZFP36 promoter by EGF
We decided to test the hypothesis that ERK-mediated
expression of TTP is regulated at the promoter level. We
therefore generated a reporter construct containing the
ZFP36 promoter fragment (-488 to +905 bp), further
abbreviated as ZFP36. The promoter fragment included
the first exon, intron and the upstream promoter sequence
of ZFP36 gene. This promoter fragment was activated
after EGF treatment, and this activation was blocked by
the ERK1/2 pathway inhibitor, U0126 (Figure 2A). ELK-1,
a well-characterized substrate of ERK1/2, is phosphory-
lated on Ser383 after ERK1/2 activation. We therefore
investigated ELK-1 Ser383 phosphorylation status upon
EGF treatment, and observed an increase after 15 minutes
of EGF stimulation (Figure 2B). As all canonical MAPK
are capable of phosphorylating ELK-1 on Ser383, we
found that inhibition of ERK1/2 using U0126 abrogated
the observed phosphorylation. We also confirmed the
expression of ELK-1 in MCF-7 cells at the protein level,
and found that ELK-1 level was relatively high in compari-
son to other tested cell lines (Figure 2C).
Having shown that ELK-1 is activated by ERK1/2 in
response to EGF stimulation, we checked whether the
promoter of ZFP36 is the target of ELK-1 regulation. For
this purpose we used the ZFP36 reporter vector and
expression vectors for constitutively active and domi-
nant-negative forms of ELK-1, Elk-VP16 and Elk-EN,
respectively. Due to the presence of strong and non-
facultative activation (VP16) or repression (EN) domains
fused in frame with C-terminus of ELK-1, the transcrip-
tion factor acts independently of MAPK activation while
preserving the DNA binding specificity [27]. ZFP36 is
activated by Elk-VP16 and repressed by Elk-EN in a
dose-dependent manner (Figure 2D). The intensity of
activation of the promoter by Elk-VP16 is much stronger
than the intensity of activation observed after EGF treat-
ment. One possible explanation of this phenomenon may
be that VP16 domain conjugated to ELK-1 is more
Figure 2 Activation of ZFP36 promoter upon EGF stimulation. (A) MCF-7 or HEK293 cells were transfected with reporter vector containing
full-length ZFP36 promoter fragment (-488 to +905 bp) and, where indicated, with ELK-1 expression vector (pExpELK-1). 24 hrs after transfection
cells were stimulated for 8 hrs with EGF with or without U0126 pretreatment and then luciferase activity was measured. (B) Serum-starved MCF-
7 cells were stimulated with EGF (20 ng/ml) for indicated times, harvested and subjected to Western blot analysis (with anti-phospho ELK-1 and
anti-GAPDH antibodies as loading control). Asterisk indicates unspecific band (C) The total cellular proteins from different cell lines were isolated
and subjected to Western blot analysis (with anti-ELK-1 antibody and anti-GAPDH antibodies as loading control). (D) MCF-7 cells were co-
transfected with reporter vector containing full-length ZFP36 promoter fragment (-488 to +905 bp) and indicated amounts of pElk-EN or pElk-
VP16. 24 hrs after transfection luciferase activity was measured. (A and D) Representative results from three independent experiments are shown
and plotted as means ± SD (n = 3)
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powerful on ZFP36 promoter than phosphorylated form
of ELK-1. Dose-dependent regulation of activation/
repression of ZFP36 promoter by Elk-VP16 or Elk-EN
suggests that observed regulation is specific.
In the mock-transfected MCF-7 cells, EGF stimulation
caused an increase in promoter activity, which was com-
pletely abolished by the inhibition of ERK1/2 (Figure 2A).
The transient overexpression of native ELK-1 did not
change the fold of stimulation by EGF in MCF-7 cell line,
which already expresses high levels of endogenous ELK-1
(Figure 2C). In HEK293 cell line with very low level of
ELK-1 (Figure 2C) the overexpression of this transcrip-
tion factor restored the responsiveness of ZFP36 promo-
ter to EGF. In MCF-7 as well as ELK-1 transfected
HEK293 cells the EGF-dependent activation of the pro-
moter was blocked by U0126. This made us conclude,
that ELK-1 can be engaged in the regulation of ZFP36
promoter after EGF stimulation. These findings were
further supported by the results obtained by qPCR. In
ELK-1-limited HEK293 cells the stimulation of TTP
expression by EGF is not observed (data not shown).
Sequences in ZFP36 promoter responsible for ELK-1
regulation
In order to find sequences involved in the observed reg-
ulation of ZFP36 promoter by ELK-1 we designed a
series of truncation mutants. Deletion of two regions,
-293 to -103 bp and +744 to +905 bp, has resulted in a
substantial decrease in promoter activation by Elk-VP16
(Figure 3).
The region -293 to -103 bp contains two EBS sites
(EGR-1 binding sites), namely EBS2 and EBS3 and one
AP-1 binding site (Figure 4A). We introduced point-
mutations into each of these sites (dEBS2, dEBS3 or
dAP-1) in the full-length ZFP36 promoter. Results of
these experiments exclude the role of AP-1 and EBS2
binding sites in the investigated regulation (Figure 4B),
despite the fact that ELK-1 can stimulate the expression
of both c-FOS (AP-1 component) and EGR-1 in MCF-7
cell line after EGF treatment (Figure 4D). Only the muta-
tion of EBS3 sequence resulted in 30% decrease in ZFP36
promoter activation by Elk-VP16 (Figure 4B). Compari-
son of the sequence of TTP gene in different species
revealed the presence of conservative elements in this
region (Figure 4C). Importance of murine homologue of
human EBS3 in serum responsiveness was already shown
earlier [18]. We have confirmed the involvement of EGR-
1 in the regulation of ZFP36 promoter by experiments
with siRNA against EGR-1. The knockdown of EGR-1 in
MCF-7 cells caused the lack of activation of ZFP36 pro-
moter by EGF (Figure 4E). Taken together, we conclude
Figure 3 Activation of ZFP36 promoter by Elk-VP16. A series of deletion mutants of ZFP36 promoter was cloned and co-transfected into
MCF-7 cells with/without 50 ng pElkVP16. 24 hrs after transfection cells were harvested and luciferase activity was measured. Results from three
independent experiments are normalized to the mock-transfected control (without pElk-VP16) and plotted as means ± SD (n = 3), * P < 0,05,
** P < 0,01, ***P < 0,001
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that EGR-1 by possible interaction with EBS3 site can
upregulate the activity of ZFP36 promoter.
The region +744 to +905 bp contains three ETS
sequences (ETS3, ETS4 and ETS5) which potentially can
bind transcription factors from the ETS family and EBS6
sequence which can potentially interact with EGR-1
(Figure 5A). We have generated point-mutations of
ETS3, ETS4 or EBS6 and deletion mutation of ETS5 in
the full-length ZFP36 promoter (dETS3, dETS4, dETS5
or dEBS6). Despite high degree (90%) of conservation of
EBS6 sequence among analyzed species (Figure 5B), its
mutation did not influence the activation of ZFP36 pro-
moter by Elk-VP16. Also mutation of ETS3 did not
result in decrease of promoter activation. Mutations of
ETS4 and ETS5 sequences leaded to about 50% reduc-
tion of Elk-VP16-induced up regulation of ZFP36 pro-
moter activity (Figure 5B). These results suggest that
ETS4 and ETS5 can participate in the regulation of
ZFP36 promoter activity by ELK-1.
Since deletions of the regions containing EBS3 or
ETS4/ETS5 (mutants F3 and R0 respectively) did not
result in a loss of dose-dependent responsiveness to Elk-
VP16 we decided to check whether deletion of both
regions (mutant R5) will abolish this regulation. The
results indicate that both investigated regions (-293 to
-103 bp and +744 to +905 bp) are jointly needed for the
regulation of ZFP36. Removing of both of them resulted
in a loss of dose-dependent regulation of ZFP36 promo-
ter by Elk-VP16 (Figure 6A).
To confirm the binding of EGR-1 to the sequence
located -293 to -103 bp and the binding of ELK-1 to the
sequence located +744 to +905 bp chromatin immunopre-
cipitation was performed. The lysates from MCF-7 cells
were immunoprecipitated with anti-EGR-1, anti-ELK-1 or
Figure 4 Analysis of importance of sequences present in -293 to -102 bp ZFP36 promoter fragment. (A) The potential transcription factor
binding sites, identified in analyzed promoter fragment by Alibaba 2.1 and TRANSFAC 6.0 programs, are shown. (B) MCF-7 cells were co-
transfected with full-length wild type ZFP36 promoter or with mutation in EBS2 (dEBS2), AP-1 (dAP-1) or EBS3 (dEBS3) and 50 ng of pElk-VP16. 24
hrs after transfection luciferase activity was measured. Results are shown as a percentage of activation of mutated variant of the promoter in
comparison to the full length -488 to +905 bp fragment, both stimulated with Elk-VP16. Data are presented as mean value ± SD from three
independent experiments (**P < 0,01) (C) -292 to -102 bp fragments of ZFP36 promoter originating from different species were analyzed using
the Emboss suite of programs. Sequence homologues were found by direct search across EMBL database and pairwase alignment with Smith-
Waterman algorithm, using standard parameters (GOP = 10, GEP = 1). Figure shows results of multiple alignment performed with ClustalW2
program (GOP = 10, GEP = 5) and the color-highlighted fragments point the transcription factors binding sites, identified by TESS program
working on TRANSFAC6 database, and potentially important for the activation of ZFP36 promoter by Elk-VP16 D) Serum-starved MCF-7 cells were
stimulated with EGF (20 ng/ml) or PMA (100 ng/ml) for 2 hrs with or without U0126 pretreatment. Then the cells were harvested and subjected
to the Western blot analysis with anti-EGR-1, anti-c-FOS and anti-GAPDH antibodies. (E) The MCF-7 cells were co-transfected with ZFP36 and
pExpELK-1 and either EGR-1 targeted siRNA or control siRNA. 18 hrs after transfection serum-starved cells were stimulated with EGF (20 ng/ml) or
PMA (100 ng/ml) for 8 hrs. The relative luciferase activity was measured. The bottom panel shows the results of Western blot analysis with anti-
EGR or anti-GAPDH antibodies in the lysates collectted from serum-starved MCF-7 cells transfected with EGR-1 targeted siRNA or control siRNA
and stimulated 2 hrs with EGF or PMA.
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nonspecific antibody. By PCR with primers flanking the
investigated sequences, the levels of immunoprecipitated
promoter sequences was analyzed. We have observed
increased level of -293 to -103 bp amplicon after immuno-
precipitation with anti-EGR-1 antibody, in comparison to
the level of template immunoprecipitated with anti-ELK-1
or nonspecific IgG (Figure 6B lower panel). When the pri-
mers flanking the region +744 to +905 bp were used, we
have observed a higher amplification in samples immuno-
precipitated with anti-ELK-1 antibody (Figure 6B upper
Figure 5 Analysis of importance of sequences present in +745 to +905 bp of ZFP36 promoter fragment. (A) The potential transcription
factor binding sites identified in analyzed promoter fragment by Alibaba 2.1 and TRANSFAC 6.0 programs are shown. (B) MCF-7 cells were co-
transfected with ZFP36 wild type or ZFP36 with mutation in ETS-3 (dETS-3), ETS-4 (dETS-4), ETS-5(dETS-5) or EBS6 (dEBS6) and 50 ng of pElk-
VP16. 24 hrs after transfection luciferase activity was measured. (C) The multiple alignment of analyzed ZFP36 promoter fragment sequence
homologues was performed by means of ClustalW2 program from the Emboss suite (GOP = 10, GEP = 5)
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panel). These results made us conclude that in vivo EGR-1
interacts with promoter sequence at the region -293 to
-103 bp and ELK-1 interacts with the region +744 to +905
bp.
Discussion
Our research focused on the mechanisms of TTP tran-
script induction by EGF in a cellular model of human
breast cancer, using MCF-7 cell line. Our data indicate
that the expression is under a stringent control of
ERK1/2-dependent pathway. The activation of ZFP36
promoter by EGF is abolished when ERK1/2 pathway
inhibitor, U0126, is present (Figure 1A, 2A). Dose-
dependent regulation of investigated promoter (-488 to
+905 bp) by constitutively active (Elk-VP16) and domi-
nant-negative (Elk-EN) forms of ELK-1, suggests invol-
vement of this transcription factor in the regulation of
TTP transcription (Figure 2D). The dose-dependent
activation of the investigated promoter by Elk-VP16 is
lost when both regions of the promoter (-293 to -103
bp and +744 to +905 bp) are removed (Figure 6A). The
region +744 to +905 bp contains two ETS sites (ETS4
and ETS5) important for the activation of the ZFP36
promoter by Elk-VP16. The sequence of ETS4 is
GCGGAA, whereas the most frequent motif recognized
by ELK-1 is CCGGAA. Such motif was characterized in
EGR-1, TR3, Pip92, MCL-1 and SRF promoters [28-30].
However in other known ELK-1 target genes modifica-
tions of this canonical sequence are present. In c-FOS
promoter ELK-1 binds to CAGGAT, in nur77 promoter
to GAGGAA, in MCPIP-1 and PAI-1 to CAGGAA
[27,29,31,32]. In the sequence of ETS5 (CAGGAG), the
GGA core is preserved but the rest of the sequence is
changed in respect to the canonical one (CCGGAA).
The ETS4 and ETS5 sequences are located in close
proximity and the disruption of any of them results in
Figure 6 Binding of ELK-1 and EGR-1 to ZFP36 promoter. (A) MCF-7 cells were co-transfected with wild type ZFP36 and ZFP36 deletion
mutant R5 (without -293 to -102 bp and +745 to +905 bp promoter fragment) and with or without pElk-VP16 (50 or 100 ng). 24 hrs after
transfection luciferase activity was measured. Representative results from three independent experiments are shown and plotted as means ± SD
(n = 3). (**P < 0,01). (B) Chromatin immunoprecipitation of transcription factors bound to ZFP36 promoter. Sonicated chromatin from MCF-7
cells grown in 10% FCS medium was immunoptrecipitated with either an ati-ELK-1 or anti-EGR-1 antibody or nonspecific IgG. PCR analysis of
eluted DNA was performed using oligonucleotides specific for the distal region (upper panel) or proximal region (lower panel). 2% of input DNA
is shown. The panels shown are inverted images of ethidium bromide-stained gels.
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the similar effect (Figure 5B), which may suggest that
ETS4 and ETS5 are in a functional relationship. A coop-
eration between proteins from ETS family was already
described for promoters of stromelisine-1 and p53,
where two Ets-1 proteins have to bind to the promoters
to obtain their full activation. Recognition of ETS
sequence through first Ets-1 molecule and its interaction
with the second Ets-1 molecule results in conforma-
tional changes and formation of complex with DNA.
This type of interaction between proteins and DNA
enhances the affinity of the second transcription factor,
even to the sequence which is not canonical [33,34]. It
could not be excluded that ELK-1 forms a complex with
other protein from ETS family on the ZFP36 promoter,
especially that such complexes were described on other
promoters [35-37]. For instance, the formation of hetero-
dimer between Ets-1 and ELK-1 is a key step in the regula-
tion of DPP-III gene expression. The C-terminal domain
of ELK-1 and the N-terminal domain of Ets-1 are engaged
in this interaction so that ETS sequences participating in
this process have to be arranged in the orientation “head
to tail”. Such orientation of ETS4 and ETS5 is present in
ZFP36 promoter which rises the possibility of such hetero-
dimer formation on the investigated promoter.
EBS3 located at -111 to -103 bp turned out to be
another sequence important for the regulation of human
ZFP36 promoter by ELK-1 (Figure 4B). Murine EBS3
homologue was already shown to play a role in the regula-
tion of Zfp36 promoter after serum stimulation [18].
ELK-1 activates ZFP36 promoter through EBS3 indir-
ectly by stimulation of EGR-1 transcription which in turn
binds to EBS3. Knockdown of EGR-1 in MCF-7 cells abro-
gates the activation of ZFP36 promoter by EGF (Figure
4E). Two other investigated EBS sequences (EBS2 located
upstream from +1 and EBS6 located in the first intron) do
not take part in the regulation of ZFP36 promoter by EGF.
Also AP-1 binding site, despite activation of c-FOS by EGF
in MCF-7 cell line (Figure 4D), is not important for the
activation of TTP promoter by EGF. Lai et al [18]
described the contribution of EBS3, AP2 and TPE1 (TTP
promoter element 1) to the serum induction of murine
Zfp36 promoter. Despite very high degree of conservation
of all these elements in human and murine promoter we
have detected only the importance of EBS3 in the regula-
tion of human ZFP36 promoter by EGF.
We hypothesize that the regions containing EBS3 and
ETS4/ETS5 are equally important for the stimulation of
TTP expression by EGF. Removing of both regions
resulted in a complete loss of dose-dependent regulation
of the promoter by Elk-VP16 (Figure 6A) and point muta-
tions of any of these sites abrogated the EGF-dependent
promoter activation (data not shown). Elimination of
EGR-1 from the cells causes the same effect (Figure 4E).
Neither EBS3 nor ETS4/5 site is sufficient enough to drive
the activation of ZFP36 promoter alone. The binding of
ELK-1 and EGR-1 to ZFP36 promoter detected by means
of chromatin immunoprecipitation confirmed involvement
of these transcription factors in the regulation of TTP
expression.
Conclusions
EGF regulates ZFP36 expression through activation of
transcription factor ELK-1. ELK-1 binds directly to the
ZFP36 promoter through the sequences localized at +
883 to +905 bp. ELK-1 induces also the expression of
another transcription factor EGR-1 which as well binds
to the ZFP36 promoter to the sequence at -111 to -103
bp (Figure 7). TTP was shown to negatively modulate a
number of factors connected with mammary gland
tumor progression. Among them IL-6, COX-2, c-FOS,
urokinase, urokinase receptor, metalloproteinase-1 can
be pointed out and notably, all of them are down-modu-
lated at their mRNA level by tristetraprolin [6,38-40].
Our results demonstrate that the expression of ZFP36 is
stimulated by EGF. The results show complex influence
of EGF on the development of breast cancer. EGF is well-
known as a factor which promotes tumor growth and
survival. This growth factor is able to induce heterodi-
merization between HER-2/Neu (c-ErbB2) and its exclu-
sive receptor c-ErbB1. Elevated levels of c-ErbB1 and
HER-2 in breast cancer is correlated with high disease
recurrence rates and decreased patient survival [41].
Upregulation of TTP expression by EGF described in this
paper reveals unexpected influence of EGF on breast can-
cer development. TTP expression is diminished in many
cancers and overexpression of TTP in tumors delayed
tumor growth and vascularization [42-44]. Thus induc-
tion of TTP expression by EGF can be classified as a
anti-tumor activity of this growth factor.
Materials and methods
Cell culture
Adenocarcinoma cell line MCF-7 (ATCC No HTB-22),
human embryonic kidney epithelium cell line HEK293
(ATCC No CRL-1573), human epithelium cell line HeLa
(ATCC No CCL-2) and human hepatoma cell line
(HepG2 No CRL-10741) were cultured at 37°C and 5%
CO2. MCF-7 cells in Minimal Eagle’s Medium (MEM)
(Sigma) supplemented with 10% FBS and bovine insuline
(10 ug/ml), HEK293, HeLa and HepG2 in Dulbecco’s
modified Eagle’s Minimum Essential Medium (DMEM,
Gibco) with 1 g/L D-glucose supplemented with 10% FBS.
Reagents and cell stimulation
Cells were stimulated with EGF (20 ng/ml) or PMA
(100 ng/ml) (R&D). When applied, the inhibitor of
MEK1/2, U0126 (10 μM) (Calbiochem) was added to
the medium 30 min prior stimulation. Pre-designed
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oligonucleotide Silencer siRNA targeted to EGR-1
(Cat#16810) and control one (Cat# 4611) were supplied
by Ambion.
RNA preparation and northern blot analysis
Total RNA isolation and northern blot analysis was per-
formed as described previously [28].
Plasmid constructs
pEF1/Myc-His/lacZ is a control vector containing the gene
for b-galactosidase (Invitrogen). pElk-VP16, pElk-EN were
described before [28]. pZFP36 containing human ZFP36
promoter fragment (-488 to +905 bp) was generated by
two step PCR, using total DNA isolated from MCF-7 cells.
The first round PCR was carried out with the primer for-
ward: 5’ GTCTTCCCTCCCTTCCTCAC 3’ and reverse 5’
GTCAGGGCTCAGCGACAG 3’. Then the second round
was performed with nested primers introducing SacI and
BglII restriction sites: forward: 5’ TCGAGCTCTTCCT-
CACCCTGTCTATC 3’ and reverse: 5’ TCAGATCTCAG-
GAGGCTCTGCGGAAATG 3’. The introduced restriction
sites were used during cloning of PCR product to pGL2-
Basic reporter vector (Promega). The set of deletion
mutants was prepared using pZFP36 as a template. The
following forward primers with restriction site for SacI or
NheI were used in PCR reactions:
F1: 5’ GCTAGCCAGTTTCCTTCTACAAGCCT-
CAG 3’
F3, R5: 5’ GCTAGCCGCGTCCGGGAAG 3’
F5: 5’ GAGCTCGCGTCCGGGAAGC 3’
F6: 5’ GAGCTCGGCCCCGGCCCCGG 3
The set of promoter constructs lacking different 3’-
terminal sequences were generated with the following
reverse primers:
R01: 5’ TCAGATCTGGAACTAGAGCTTGCCAG 3’
R0, R5: 5’ TCAGATCTAGAGTTGGAGGTTCT-
GAG 3’
R1: 5’ CTTAAGCACGCGTCGGGATCTC 3’
R2: 5’ CTTAAGTTTGAGCGAAGAGCCGGGTG 3’
R4, F6, F5: 5’ GCTAGCCTCGTAGATGGCAGT-
CAG 3’
Figure 7 Schematic diagram of regulation of the ZFP36 promoter by EGF.
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The constructs containing mutations in selected tran-
scription factors’ binding sites were generated using Quik-
Change XL Site-Directed Mutagenesis kit (Stratagene)
according to the manufacturer’s procedure. The sequences
were changed as follows:
EBS2: CCCCCACCCC to CCCCCAgCtg
EBS3: CCGGGGGCG to CCatGGGCG
AP-1: CAAGCCTCAG to CAAGCCatgG
ETS3: ATCCGGAA to tgCaGccA
ETS4: ACCCATTTCC to ACCCATggCC
EBS6: GGGTGGGGCG to GGGTaccGCG
The point mutant ETS5 was created by means of dele-
tion mutation after a PCR reaction performed with a
reverse primer 5’ TCAGATCTTGCGGAAATGGGTC
GGT 3’.
Reporter gene assay
Transient transfection experiments were carried out using
Lipofectamine 2000 reagent (Invitrogen) in 12-well plate.
Total amount of 1.6 μg of DNA per each well was used,
including 0.4 μg of reporter vectors with ZFP36 promoter
fragments and 10 ng of pEF1/Myc-His/lacZ. For some
experiments indicated amounts of pElk-VP16 or pElk-EN
were used. The amount of DNA per well was equalized
using mock DNA (pcDNA3). Luciferase assays were car-
ried out using the dual light reporter gene assay system
(Tropix) according to the manufacturer’s procedure. Luci-
ferase activity was measured 24 hrs after transfection or at
indicated time point after stimulation. b-galactosidase
activity was measured to normalize the efficiency of trans-
fection. All experiments were repeated at least three times
in duplicates.
Western blot
Western blot was carried out using Immobilon Western
chemiluminescent HRP substrate (Millipore) and anti-
phospho ERK1/2 (Cell Signaling), anti-ELK-1 (Santa
Cruz), anti- phospho p38 (Cell Signaling), anti-phospho
JNK (Abcam), anti-c-FOS (Santa Cruz), anti-EGR-1
(Abcam), anti-GAPDH (Abcam), anti-phospho Ser383
ELK-1 (Santa Cruz), anti-ERK, anti-p38, anti-JNK (Cell
Signalling).
siRNA/DNA co-transfection
Was carried out using Lipofectamine 2000 reagent (Invi-
trogen) in 12-well plate. Total amount of 600 ng plasmid
DNA and 50 pmol siRNA oligonucleotides per each well
was used.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was carried out as
described before [28] using anti-ELK-1, anti-EGR-1
(Santa Cruz) and nonspecific IgG (Upstate). Following
primers forward: ACCTCCAACTCTGGGTTCCT and
reverse: GACTCAGTCCCTCCATGGTC for fragment
containing ETS4/5 sites and forward: CGGAAGG-
GAACCAGTCCAG and reverse: AGAGTGGGAGCG
CTGAAGT for fragment containing EBS3 binding site
were used.
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